Vivani Medical, Inc. (VANI), on Wednesday, announced promising preclinical data for its semaglutide implant in development ...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for ...

Vivani Medical, Inc. (NASDAQ: VANI) shares dropped in price Wednesday, as the Alameda, Calif.-based clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Vivani Medical (VANI) announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

Maravai LifeSciences Holdings Inc (MRVI) is expected to report $-0.07 for 4Q. McCormick & Co Inc (MKC) is expected to report $0.64 for 1Q. Movado Group Inc (MOV) is expected to report $0.39 for 4Q.

Smartkem , which is seeking to change the world of electronics with a new class of transistor technology, has announced a memorandum of understanding with RiTdisplay Corporation, a leading developer ...

Corporate Insight (CI), the leading provider of competitive intelligence and customer experience research, today announced the release of its Health System Monitor Pace of Change report, a new ...

Vivani Medical (NASDAQ:VANI – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ...

Meanwhile, Vivani Medical has implanted the first patient with its weight loss device. Give your business an edge with our leading industry insights. Give your business an edge with our leading ...

Vivani Medical (VANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).